SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Donald Gravenor who wrote (71)2/2/1997 3:08:00 PM
From: GuinnessGuy   of 1321
 
Donald,

>most esophageal and lung
cancers are too far advanced to benefit from what seems to be a superficial
treatment (eg photofrin).<

I was under the impression that photofrin would be used as a third modality for the treatment of such cancers and rarely, if ever, just by itself. For this reason its use for cancer treatment could still be
widely used...no?

>can now do something useful
to restore sight in the elderly (other than caterracts). This will increase the use of the
QLT drug, with a bit of help from demographics.

My memory may be failing here but I thought that in the treatment of
age-related macular degeneration that QLT's treatment would halt the
advancement of the disease and not actually restore visional acuity
that had already been lost. TIA

Regards...Craig
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News